← Leaderboards
Steven Armen Boyd
Venatorx Pharmaceuticals, Inc.
$13,685,544
Attributed
$13,685,544
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,685,544 · 2
By mechanism
R01$13,685,544 · 2
Top collaborators
No co-investigators on record.
Most similar at Venatorx Pharmaceuticals, Inc.
Same institution · by research overlap
- Luigi Xerri$39,662,982
- Denis Marc Daigle$7,512,530
- Bin Liu$3,147,000
- Tsuyoshi Uehara$2,000,000
- Randy Jackson$150,000
Others in their field
Other Emerging Leaders on “Innovation”
- Klaus Romero · Critical Path Institute$86,053,372
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$69,953,681
- Tony Moody · Duke University$65,625,959
- Matthew Johnson · Duke University$60,590,296
Research focus
InnovationMicrobiologyPharmaceutical PreparationsPathogenPropertyBeta-LactamaseEscherichia ColiGram-Negative BacteriaIn VitroPenicillin-Binding ProteinsProgramsAntibioticsBeta-LactamsStructureAnti-Bacterial AgentsDesignFutureExhibitsBactericideBaseBiologicalBindingDoseCeftazidime
Grant awards (10)
Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections$1,220,775
R01 · FY2025 · AI · contact PI
Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections$1,220,775
R01 · FY2024 · AI · contact PI
Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections$1,220,775
R01 · FY2023 · AI · contact PI
Establishing a Gram-Negative Permeation Rule Set Leveraging a Unique Small Molecule Library$1,477,022
R01 · FY2022 · AI · contact PI
Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections$1,183,227
R01 · FY2022 · AI · contact PI
Establishing a Gram-Negative Permeation Rule Set Leveraging a Unique Small Molecule Library$1,494,033
R01 · FY2021 · AI · contact PI
Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections$1,483,227
R01 · FY2021 · AI · contact PI
Establishing a Gram-Negative Permeation Rule Set Leveraging a Unique Small Molecule Library$1,294,532
R01 · FY2020 · AI · contact PI
Establishing a Gram-Negative Permeation Rule Set Leveraging a Unique Small Molecule Library$1,237,778
R01 · FY2019 · AI · contact PI
Establishing a Gram-Negative Permeation Rule Set Leveraging a Unique Small Molecule Library$1,853,400
R01 · FY2018 · AI · contact PI